share_log

Cantor Fitzgerald Reiterates Overweight on Fulcrum Therapeutics, Maintains $23 Price Target

Cantor Fitzgerald Reiterates Overweight on Fulcrum Therapeutics, Maintains $23 Price Target

康泰菲利兹证券重申对fulcrum therapeutics的看好评级,维持23美元的价格目标。
Benzinga ·  07/10 10:10

Cantor Fitzgerald analyst Kristen Kluska reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and maintains $23 price target.

Cantor Fitzgerald分析师Kristen Kluska重申对fulcrum therapeutics(纳斯达克:FULC)的超重评级,并维持23美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发